TD Asset Management’s Blueprint Medicines BPMC Stock Holding History

TD Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-77,100	Closed	-$9.88M	–	1244
2025 Q2	$9.88M	Sell	77,100 -207,272	-73%	-$21.5M	0.01%	636
2025 Q1	$25.2M	Sell	284,372 -19,128	-6%	-$1.87M	0.02%	455
2024 Q4	$26.5M	Buy	303,500 +37,000	+14%	+$3.39M	0.02%	451
2024 Q3	$24.7M	Sell	266,500 -57,000	-18%	-$5.66M	0.02%	465
2024 Q2	$34.9M	Sell	323,500 -59,970	-16%	-$6M	0.03%	354
2024 Q1	$36.4M	Buy	383,470 +87,554	+30%	+$7.51M	0.03%	351
2023 Q4	$27.3M	Sell	295,916 -20,388	-6%	-$1.32M	0.03%	397
2023 Q3	$15.9M	Buy	316,304 +124,792	+65%	+$6.67M	0.02%	485
2023 Q2	$12.1M	Buy	191,512 +24,160	+14%	+$1.31M	0.01%	552
2023 Q1	$7.53M	Buy	167,352 +24,228	+17%	+$1.09M	0.01%	659
2022 Q4	$6.27M	Buy	143,124 +16,200	+13%	+$777K	0.01%	685
2022 Q3	$8.36M	Buy	126,924 +30,900	+32%	+$1.98M	0.01%	635
2022 Q2	$4.85M	Sell	96,024 -5,000	-5%	-$293K	0.01%	780
2022 Q1	$6.45M	Sell	101,024 -4,878	-5%	-$350K	0.01%	764
2021 Q4	$11.3M	Buy	105,902 +23,164	+28%	+$2.42M	0.01%	647
2021 Q3	$8.51M	Buy	82,738 +6,300	+8%	+$587K	0.01%	689
2021 Q2	$6.72M	Buy	76,438 +1,014	+1%	+$92.9K	0.01%	759
2021 Q1	$7.33M	Buy	75,424 +9,315	+14%	+$930K	0.01%	723
2020 Q4	$7.41M	Buy	66,109 +6,114	+10%	+$644K	0.01%	682
2020 Q3	$5.56M	Buy	59,995 +1,100	+2%	+$84.7K	0.01%	676
2020 Q2	$4.59M	Buy	58,895 +2,300	+4%	+$156K	0.01%	681
2020 Q1	$3.31M	Sell	56,595 -2,523	-4%	-$162K	0.01%	720
2019 Q4	$4.74M	Sell	59,118 -8,000	-12%	-$599K	0.01%	724
2019 Q3	$4.93M	Sell	67,118 -3,000	-4%	-$259K	0.01%	688
2019 Q2	$6.61M	Buy	70,118 +7,393	+12%	+$610K	0.01%	624
2019 Q1	$5.02M	Sell	62,725 -300	-0.5%	-$22.2K	0.01%	692
2018 Q4	$3.4M	Buy	63,025 +1,500	+2%	+$91.2K	0.01%	777
2018 Q3	$4.8M	Sell	61,525 -1,200	-2%	-$83.4K	0.01%	740
2018 Q2	$3.98M	Sell	62,725 -930	-1%	-$74K	0.01%	766
2018 Q1	$5.84M	Buy	63,655 +2,900	+5%	+$250K	0.01%	639
2017 Q4	$4.58M	Buy	60,755 +9,215	+18%	+$648K	0.01%	691
2017 Q3	$3.59M	Buy	51,540 +2,886	+6%	+$154K	0.01%	741
2017 Q2	$2.46M	Buy	48,654 +7,000	+17%	+$297K	﹤0.01%	827
2017 Q1	$1.67M	Buy	41,654 +24,415	+142%	+$874K	﹤0.01%	927
2016 Q4	$484K	Buy	17,239 +7,439	+76%	+$224K	﹤0.01%	1188
2016 Q3	$291K	Sell	9,800 -2,500	-20%	-$62.1K	﹤0.01%	1313
2016 Q2	$249K	Hold	12,300	–	–	﹤0.01%	1290
2016 Q1	$222K	Sell	12,300 -800	-6%	-$13.9K	﹤0.01%	1287
2015 Q4	$345K	Hold	13,100	–	–	﹤0.01%	1208
2015 Q3	$280K	Buy	13,100 +100	+0.8%	+$2.77K	﹤0.01%	1211
2015 Q2	$344K	Buy	+13,000	New	+$371K	﹤0.01%	1220

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

TD Asset Management's BPMC Position: Q3 2025 in Review

TD Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 77,100 shares — an estimated $9.88M sold.

TD Asset Management first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $36.4M in Q1 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

TD Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
TD Asset Management sold 77,100 Blueprint Medicines shares in Q3 2025, an estimated $9.88M.
TD Asset Management first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
TD Asset Management's Blueprint Medicines position peaked at $36.4M in Q1 2024.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on TD Asset Management's 13F filing for Q3 2025, filed 10 Nov 2025.